NCT05571111View on ClinicalTrials.gov

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 4, 2022

Primary Completion Date

March 25, 2024

Study Completion Date

June 25, 2024

Conditions
Infertility
Interventions
DRUG

FE 999302

Subcutaneous injection as a single dose. 3 different doses

DRUG

Ovitrelle

Subcutaneous injection as a single dose. 250 µg (0.5 mL)

DRUG

Novarel

Subcutaneous injection as a single dose. 10,000 IU (1 mL)

Trial Locations (3)

28023

Ferring Investigational Site, Madrid

41092

Ferring Investigational Site, Seville

46015

Ferring Investigational Site, Valencia

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY